

Yasushi Isobe

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1451768/publications.pdf>

Version: 2024-02-01

11
papers

755
citations

1163117

8
h-index

1372567

10
g-index

11
all docs

11
docs citations

11
times ranked

1100
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficient recruitment of cFLIP L to the death-inducing signaling complex leads to Fas resistance in natural killer cell lymphoma. <i>Cancer Science</i> , 2020, 111, 807-816.	3.9	3
2	Targeting BCL2 with venetoclax is a promising therapeutic strategy for double-protein-expression lymphoma with MYC and BCL2 rearrangements. <i>Haematologica</i> , 2019, 104, 1417-1421.	3.5	16
3	Expression of activating natural killer cell receptors is a hallmark of the innate-like T cell neoplasm in peripheral T cell lymphomas. <i>Cancer Science</i> , 2018, 109, 1254-1262.	3.9	9
4	A portion of expanded granular lymphocytes cause pure white cell aplasia?. <i>Annals of Hematology</i> , 2018, 97, 1995-1997.	1.8	1
5	De novo acute lymphoblastic leukemia-like disease of high grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements: a case report and literature review. <i>BMC Clinical Pathology</i> , 2017, 17, 21.	1.8	12
6	A monoclonal expansion of Epstein-Barr virus-infected natural killer cells after allogeneic peripheral blood stem cell transplantation. <i>Journal of Clinical Virology</i> , 2013, 56, 150-152.	3.1	0
7	T/NK cell type chronic active Epstein-Barr virus disease in adults: an underlying condition for Epstein-Barr virus-associated T/NK-cell lymphoma. <i>Journal of Clinical Pathology</i> , 2012, 65, 278-282.	2.0	51
8	Expression of Epstein-Barr Virus-Encoded Proteins in Extranodal NK/T-cell Lymphoma, Nasal Type (ENKL): Differences in Biologic and Clinical Behaviors of LMP1-Positive and -Negative ENKL. <i>Clinical Cancer Research</i> , 2012, 18, 2164-2172.	7.0	43
9	Phase II Study of SMILE Chemotherapy for Newly Diagnosed Stage IV, Relapsed, or Refractory Extranodal Natural Killer (NK)/T-Cell Lymphoma, Nasal Type: The NK-Cell Tumor Study Group Study. <i>Journal of Clinical Oncology</i> , 2011, 29, 4410-4416.	1.6	532
10	Activity and safety of combination chemotherapy with methotrexate, ifosfamide, L-asparaginase and dexamethasone (MILD) for refractory lymphoid malignancies: a pilot study. <i>European Journal of Haematology</i> , 2010, 84, 310-315.	2.2	11
11	Epstein-Barr Virus Infection of Human Natural Killer Cell Lines and Peripheral Blood Natural Killer Cells. <i>Cancer Research</i> , 2004, 64, 2167-2174.	0.9	77